We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$406M
Cap. Flow
+$12.3M
Cap. Flow %
0.52%
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
25
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$32.6M
2
LLY icon
Eli Lilly
LLY
+$25.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.3M
5
WELL.PRI
Welltower Inc.
WELL.PRI
+$11.7M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$58.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.9M
3
ILMN icon
Illumina
ILMN
+$13.4M
4
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$12.5M
5
ALR
Alere Inc
ALR
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.12%
2 Real Estate 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$214M 9.11%
2,331,231
– –
CELG
2
DELISTED
Celgene Corp
CELG
$175M 7.44%
1,747,234
+33,600
+2% +$3.46M
BIIB icon
3
Biogen
BIIB
$30.7B
$117M 4.99%
450,533
– –
AGN
4
DELISTED
Allergan plc
AGN
$110M 4.67%
409,586
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$88.7M 3.77%
636,805
– –
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$122B
$82.2M 3.49%
1,033,503
– –
INCY icon
7
Incyte
INCY
$24.9B
$69.3M 2.95%
956,461
+76,000
+9% +$5.66M
ILMN icon
8
Illumina
ILMN
$31B
$56.6M 2.41%
358,632
-87,871
-20% -$13.4M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$77.4B
$55.6M 2.36%
154,266
– –
PFE icon
10
Pfizer
PFE
$142B
$53.7M 2.28%
1,909,860
+10,245
+0.5% +$293K
UNH icon
11
UnitedHealth
UNH
$383B
$52.7M 2.24%
409,100
– –
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.7B
$49.2M 2.09%
596,145
– –
AMGN icon
13
Amgen
AMGN
$209B
$48.2M 2.05%
321,640
– –
MDT icon
14
Medtronic
MDT
$110B
$41.8M 1.78%
557,104
+432,760
+348% +$32.6M
JNJ icon
15
Johnson & Johnson
JNJ
$617B
$40.6M 1.73%
375,088
-565,900
-60% -$58.6M
MRK icon
16
Merck
MRK
$321B
$36M 1.53%
713,790
– –
TEVA icon
17
Teva Pharmaceuticals
TEVA
$41.2B
$36M 1.53%
671,958
-662,279
-50% -$38.9M
SHPG
18
DELISTED
Shire pic
SHPG
$34.7M 1.47%
201,713
+29,900
+17% +$5.01M
MDVN
19
DELISTED
MEDIVATION, INC.
MDVN
$30.7M 1.3%
667,300
– –
LLY icon
20
Eli Lilly
LLY
$1.03T
$30M 1.28%
417,167
+331,500
+387% +$25.1M
VTRS icon
21
Viatris
VTRS
$20.7B
$28.6M 1.22%
617,952
+86,700
+16% +$4.18M
A icon
22
Agilent Technologies
A
$39.2B
$28.4M 1.21%
713,850
-14,800
-2% -$564K
HCA icon
23
HCA Healthcare
HCA
$85.7B
$26.1M 1.11%
334,998
-113,490
-25% -$7.92M
HUM icon
24
Humana
HUM
$44B
$23.7M 1.01%
129,300
– –
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$16.2B
$23.4M 0.99%
+179,091
New +$22.3M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Tekla Capital Management held 145 positions worth $2.35B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management's Q1 2016 filing shows 11 new, 25 increased, 9 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 179,091 shares worth $23.4M. The largest sale was Johnson & Johnson, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2016 buy was Jazz Pharmaceuticals: 179,091 shares worth $23.4M.
  • Tekla Capital Management added most to Medtronic in Q1 2016, an estimated $32.6M increase.
  • Tekla Capital Management's biggest Q1 2016 reduction was Johnson & Johnson, cutting an estimated $58.6M.
  • Tekla Capital Management fully exited BAXALTA INC COM STK (DE) in Q1 2016, selling an estimated $12.5M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.35B portfolio in Q1 2016.
  • Tekla Capital Management opened 11 new positions and closed 5 in Q1 2016.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q1 2016, filed 9 May 2016.